Continued triple digit growth from GI Genius®, double digit growth from Winlevi® and steady growth from Gastro and CDMO business. Increased R&D spending to advance Phase II programs for Bile Acid ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Cosmo (SWX:COPN) announced that its commercial partner Glenmark Specialty has ...
Dublin, Ireland--(Newsfile Corp. - March 9, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today reports its audited financial results for the fiscal year ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results